Strategic reviews, sales and spinoffs are trendy in Big Pharma these days. Now, the Danish drugmaker Novo Nordisk has joined the bunch. Novo says it's weighing an initial public offering for its IT subsidiary, NNIT, and has hired a new CFO for the unit to handle the review.
Roche didn't waste much time in replacing former R&D guru Hal Barron, tapping oncology head Sandra Horning to serve as its next chief medical officer and head of global product development.
Novartis is saying goodbye to the man who steered its cancer business. Hervé Hoppenot, president of Novartis Oncology, has jumped ship for the CEO job at Incyte, one of the Swiss drugmaker's longtime development partners.
The company named Michael Kelly, an 11-year Amgen veteran, to hold the CFO position on an interim basis.
Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...
Sigal is joining New Enterprise Associates, where former MedImmune CEO David Mott has been leading the healthcare crew.
Departed CEO Jeremy Levin officially has a successor at Teva Pharmaceutical Industries. As predicted, Erez Vigodman will step into the helmsman's role as of Feb. 11, while interim CEO Eyal Desheh will return to his previous position as CFO, the company said Thursday.
Teva Pharmaceutical Industries is said to be close to choosing Israeli executive Erez Vigodman to take its empty CEO chair, but as the Wall Street Journal reports, some other candidates are still in the running.
Gilead Sciences just rolled out its much-anticipated hepatitis C treatment Sovaldi (sofosbuvir) last month. Now, the company's commercial chief is saying sayonara. EVP Kevin Young will retire Feb. 4, leaving his team to soldier on alone with the Sovaldi launch.
Balky Teva shareholder Benny Landa has fallen in line behind the company's apparent choice for CEO, Erez Vigodman. As the Financial Times reports, Landa is once again circulating an email to fellow major shareholders--but this time to support the company's board rather than attack it.